Discontinued — last reported Q3 '20
BioPharma Systems — Goodwill
Becton, Dickinson and Company BioPharma Systems — Goodwill decreased by 99.6% to $96.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 99.6%, from $26.44B to $96.00M. Over 5 years (FY 2020 to FY 2025), BioPharma Systems — Goodwill shows relatively stable performance with a 1.9% CAGR.
Analysis
How to read this metric
A stable or increasing balance reflects historical acquisition activity, while a sudden decrease typically signals an impairment charge due to underperformance.
Detailed definition
This metric represents the excess purchase price paid for acquisitions attributed to the BioPharma Systems segment over...
Peer comparison
Comparable to goodwill balances in other large-cap medical technology companies that frequently utilize M&A for growth.
bdx_segment_biopharma_systems_goodwillHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $23.81B | $23.89B | $24.12B | $24.10B | $23.97B | $24.62B | $24.76B | $24.78B | $24.58B | $24.52B | $24.60B | $24.57B | $24.55B | $26.47B | $26.33B | $26.44B | $26.60B | $25.96B | $96.00M | $26.62B | $96.00M | $25.96B | $96.00M |
| QoQ Change | — | +0.3% | +1.0% | -0.1% | -0.5% | +2.7% | +0.6% | +0.1% | -0.8% | -0.3% | +0.3% | -0.1% | -0.1% | +7.8% | -0.5% | +0.4% | +0.6% | -2.4% | -99.6% | >999% | -99.6% | >999% | -99.6% |
| YoY Change | — | — | — | — | +0.6% | +3.1% | +2.7% | +2.8% | +2.6% | -0.4% | -0.7% | -0.9% | -0.2% | +7.9% | +7.0% | +7.6% | +8.4% | -1.9% | -99.6% | +1.1% | -99.6% | -1.8% | -99.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Becton, Dickinson and Company's biopharma systems — goodwill?
- Becton, Dickinson and Company (BDX) reported biopharma systems — goodwill of $96.00M in Q1 2026.
- How has Becton, Dickinson and Company's biopharma systems — goodwill changed year-over-year?
- Becton, Dickinson and Company's biopharma systems — goodwill decreased by 99.6% year-over-year, from $26.44B to $96.00M.
- What is the long-term trend for Becton, Dickinson and Company's biopharma systems — goodwill?
- Over 5 years (2020 to 2025), Becton, Dickinson and Company's biopharma systems — goodwill has grown at a 1.9% compound annual growth rate (CAGR), from $23.60B to $25.96B.
- What does biopharma systems — goodwill mean?
- The value of intangible assets like brand reputation and synergies recorded on the balance sheet for the BioPharma Systems segment following acquisitions.